Based in Santa Monica, CA, Trethera is a privately-held company that aims to develop safer, more affordable and efficacious treatments for indications in oncology. The company is capitalizing on novel insights into the metabolic demands and vulnerabilities of cancer during rapid DNA replication and is developing small molecule compounds to precisely target these pathways. By targeting multiple pathways using rationally-designed combinations of drugs, Trethera’s therapeutic approaches are designed to improve efficacy and overcome the limitations of previous single agent therapies.